Research programme: embryonic tissue xenotransplants - Tissera
Latest Information Update: 07 Apr 2014
At a glance
- Originator Weizmann Institute of Science
- Developer Tissera
- Class Cell therapies
- Mechanism of Action Tissue replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Renal failure; Type 1 diabetes mellitus